Imfinzi significantly improved overall survival and progression …
WEBApr 5, 2024 · Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial. PUBLISHED 5 April 2024. First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial. Positive high-level results of the ADRIATIC Phase III ...
IMFINZI® (durvalumab) perioperative regimen reduced the risk of ...
WEB5 days ago · IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA...
Imfinzi Improves Survival in Small Cell Lung Cancer - NCI
WEBJun 25, 2024 · The immunotherapy drug durvalumab (Imfinzi) helped people with early-stage small cell lung cancer live longer, according to initial results from a large clinical trial. Durvalumab is a type of immunotherapy called an immune checkpoint inhibitor.
Imfinzi plus Lynparza reduced the risk of disease progression or …
WEBPUBLISHED 21 October 2023. Imfinzi reduced the risk of disease progression or death by 29% vs. chemotherapy. First Phase III trial to demonstrate clinical benefit of immunotherapy plus PARP inhibition in advanced or recurrent endometrial cancer.
Imfinzi Continuously Demonstrates Survival Benefit in Limited …
WEB4 days ago · The 36-month OS rates were 62.1% versus 56.5%, respectively. Among patients who had no prior PCI in the Imfinzi (122 patients) and placebo arms (123 patients), data showed a median OS of 37.3 months and 24.1 months in each arm. After three years, the OS rates were 50.2% with Imfinzi versus 37.3% with placebo.
FDA approves neoadjuvant/adjuvant durvalumab for resectable …
WEBOn August 15, 2024, the FDA approved durvalumab (Imfinzi, AstraZeneca) with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant...
FDA expands approval of Imfinzi to reduce the risk of non-small …
WEBThe U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be...
IMFINZI plus chemotherapy tripled patient survival at three years …
WEBSep 18, 2021 · IMFINZI plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer. Longest survival follow-up ever reported for immunotherapy treatment in this setting. Updated results from the CASPIAN Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab) in combination with a ...
IMFINZI® (durvalumab) approved in the US for the treatment of ...
WEBAug 16, 2024 · As part of a broad development program, IMFINZI is being tested as a single treatment and in combinations with other anti-cancer treatments for patients with SCLC, NSCLC, breast cancer, bladder...
AIM ImmunoTech Reports Positive Preliminary Data in Phase
WEB1 day ago · Combination of Ampligen and Imfinzi continues to be generally well-tolerated with no severe adverse events or dose-limiting toxicities. OCALA, Fla., Sept. 19, 2024 (GLOBE NEWSWIRE) -- AIM ...